BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McCarthy MW, Walsh TJ. Prophylactic Measures During Induction for Acute Myeloid Leukemia. Curr Oncol Rep 2017;19:18. [PMID: 28251490 DOI: 10.1007/s11912-017-0574-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Arad-Cohen N, Rowe JM, Shachor-Meyouhas Y. Pharmacological prophylaxis of infection in pediatric acute myeloid leukemia patients. Expert Opin Pharmacother 2020;21:193-205. [PMID: 31914337 DOI: 10.1080/14656566.2019.1701654] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol 2021;:JCO2001739. [PMID: 34156898 DOI: 10.1200/JCO.20.01739] [Reference Citation Analysis]
3 McCarthy MW, Walsh TJ. Candidemia in the cancer patient: diagnosis, treatment, and future directions. Expert Rev Anti Infect Ther 2018;16:849-54. [PMID: 30322269 DOI: 10.1080/14787210.2018.1536546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
4 Vaughn JL, Kline D, Denlinger NM, Andritsos LA, Exline MC, Walker AR. Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy. Leuk Lymphoma 2018;59:1498-500. [PMID: 28901797 DOI: 10.1080/10428194.2017.1376744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
5 Acheampong DO, Adokoh CK, Asante DB, Asiamah EA, Barnie PA, Bonsu DOM, Kyei F. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Biomed Pharmacother 2018;97:225-32. [PMID: 29091870 DOI: 10.1016/j.biopha.2017.10.100] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
6 Mendes FR, da Silva WF, da Costa Bandeira de Melo R, Silveira DRA, Velloso EDRP, Rocha V, Rego EM. Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting. Ann Hematol 2021. [PMID: 34676435 DOI: 10.1007/s00277-021-04687-6] [Reference Citation Analysis]
7 Briot T, Roger E, Thépot S, Lagarce F. Advances in treatment formulations for acute myeloid leukemia. Drug Discovery Today 2018;23:1936-49. [DOI: 10.1016/j.drudis.2018.05.040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
8 Vasileiou E, Paisiou A, Tsipou C, Pourtsidis A, Galani V, Katzilakis N, Antoniadi K, Papakonstantinou E, Ioannidou E, Stiakaki E, Baka M, Kattamis A, Kitra V, Tragiannidis A. Candidemia in Children with Malignancies: Report from the Infection Working Group of the Hellenic Society of Pediatric Hematology-Oncology. J Fungi (Basel) 2020;6:E276. [PMID: 33182837 DOI: 10.3390/jof6040276] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]